uHAPs target areas in tumours that conventional cancer treatments leave behind
OncoTherics' focus concerns the biology of low oxygen areas found in most tumours and the role these "hypoxic micro-environments" play in the resistance and spread of a variety of cancers.
Our solution is to target these areas with a new class of pro-drugs, that are able to penetrate these regions and in combination with conventional therapies, deliver an effective treatment across the whole tumour.
In so doing, we are delivering a clean, targeted solution to one of cancer’s most persistent blind spots.
Opportunity
OncoTherics has developed two novel assets;
- OCT1004 - Phase II ready - Pancreatic Cancer
- OCT1002 - Late Preclinical phase - next generation uHAP
After successful execution of its preclinical development programme in the UK and Poland, OncoTherics is now seeking further investment to progress to clinical trial in the USA.
OncoTherics has been funded to date by its Founders, Private Investors and regional grant funding in Poland. OncoTherics was a beneficiary of the regional operational program of the Małopolskie Voivodeship for the years 2014-2020.
wartość projektu: 19 357 662,37 PLN
wkład funduszy Europejskich: 11 718 069,36 PLN
